Literature DB >> 19724227

Facioscapulohumeral muscular dystrophy.

George W Padberg1, Baziel Gm van Engelen.   

Abstract

PURPOSE OF REVIEW: Knowledge of the pathogenetic mechanisms in facioscapulohumeral muscular dystrophy is still scattered, but has recently been advanced through novel developments on the genetic scientific front. RECENT
FINDINGS: The present brief review highlights some recent studies on the pathogenesis of facioscapulohumeral muscular dystrophy pointing to major involvement of muscle development pathways and possibly vascular development pathways as well, which feeds into ideas about homeobox-related transcriptional dysregulation, which was originally suggested, based on the apparent descending order of muscle weakness.
SUMMARY: The present findings and observations set a broad agenda for further research and possible therapeutic targets.

Entities:  

Mesh:

Year:  2009        PMID: 19724227     DOI: 10.1097/WCO.0b013e328330a572

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  14 in total

1.  FSHD1 and FSHD2 form a disease continuum.

Authors:  Sabrina Sacconi; Audrey Briand-Suleau; Marilyn Gros; Christian Baudoin; Richard J L F Lemmers; Sophie Rondeau; Nadira Lagha; Pilvi Nigumann; Chiara Cambieri; Angela Puma; Françoise Chapon; Tanya Stojkovic; Christophe Vial; Françoise Bouhour; Michelangelo Cao; Elena Pegoraro; Philippe Petiot; Anthony Behin; Bras Marc; Bruno Eymard; Andoni Echaniz-Laguna; Pascal Laforet; Leonardo Salviati; Marc Jeanpierre; Gaël Cristofari; Silvère M van der Maarel
Journal:  Neurology       Date:  2019-04-12       Impact factor: 9.910

Review 2.  Facioscapulohumeral Dystrophy.

Authors:  Leo H Wang; Rabi Tawil
Journal:  Curr Neurol Neurosci Rep       Date:  2016-07       Impact factor: 5.081

3.  Large family cohorts of lymphoblastoid cells provide a new cellular model for investigating facioscapulohumeral muscular dystrophy.

Authors:  Takako I Jones; Charis L Himeda; Daniel P Perez; Peter L Jones
Journal:  Neuromuscul Disord       Date:  2016-12-23       Impact factor: 4.296

4.  Immunodetection of human double homeobox 4.

Authors:  Linda N Geng; Ashlee E Tyler; Stephen J Tapscott
Journal:  Hybridoma (Larchmt)       Date:  2011-04

5.  Diagnostic magnetic resonance imaging biomarkers for facioscapulohumeral muscular dystrophy identified by machine learning.

Authors:  Mauro Monforte; Sara Bortolani; Eleonora Torchia; Lara Cristiano; Francesco Laschena; Tommaso Tartaglione; Enzo Ricci; Giorgio Tasca
Journal:  J Neurol       Date:  2021-09-06       Impact factor: 4.849

6.  Elderly onset of weakness in facioscapulohumeral muscular dystrophy.

Authors:  Dominic B Fee
Journal:  Case Rep Neurol Med       Date:  2012-09-18

7.  Effect of aerobic exercise training and cognitive behavioural therapy on reduction of chronic fatigue in patients with facioscapulohumeral dystrophy: protocol of the FACTS-2-FSHD trial.

Authors:  Nicoline B M Voet; Gijs Bleijenberg; George W Padberg; Baziel G M van Engelen; Alexander C H Geurts
Journal:  BMC Neurol       Date:  2010-06-30       Impact factor: 2.474

8.  Different molecular signatures in magnetic resonance imaging-staged facioscapulohumeral muscular dystrophy muscles.

Authors:  Giorgio Tasca; Mario Pescatori; Mauro Monforte; Massimiliano Mirabella; Elisabetta Iannaccone; Roberto Frusciante; Tiziana Cubeddu; Francesco Laschena; Pierfrancesco Ottaviani; Enzo Ricci
Journal:  PLoS One       Date:  2012-06-13       Impact factor: 3.240

9.  Atypical onset in a series of 122 cases with FacioScapuloHumeral Muscular Dystrophy.

Authors:  Ebe Pastorello; Michelangelo Cao; Carlo P Trevisan
Journal:  Clin Neurol Neurosurg       Date:  2011-11-12       Impact factor: 1.876

10.  Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy.

Authors:  Takako I Jones; Oliver D King; Charis L Himeda; Sachiko Homma; Jennifer C J Chen; Mary Lou Beermann; Chi Yan; Charles P Emerson; Jeffrey B Miller; Kathryn R Wagner; Peter L Jones
Journal:  Clin Epigenetics       Date:  2015-03-29       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.